EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-15-0548-TPMID 26832794PMCID PMC4783288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis

  2015cited by this paper
• Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer

  2015cited by this paper
• Co-delivery of doxorubicin and siRNA for glioma therapy by a brain targeting system: angiopep-2-modified poly(lactic-co-glycolic acid) nanoparticles

  2015cited by this paper
• TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis

  2015cited by this paper
• Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

  2014cited by this paper
• Sumoylation pathway is required to maintain the basal breast cancer subtype.

  2014influential reference
• Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer

  2014influential reference
• TFAP2C Governs the Luminal Epithelial Phenotype in Mammary Development and Carcinogenesis

  2014influential reference
• Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

  2014cited by this paper
• EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast

  2013cited by this paper
• Expression of the RET Proto-oncogene Is Regulated by TFAP2C in Breast Cancer Independent of the Estrogen Receptor

  2013cited by this paper
• BootES: An R package for bootstrap confidence intervals on effect sizes

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

  2012cited by this paper
• bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer

  2012cited by this paper
• Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells.

  2012cited by this paper
• Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice

  2012cited by this paper
• Combinational RNAi gene therapy of hepatocellular carcinoma by targeting human EGFR and TERT.

  2011cited by this paper
• Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action

  2011cited by this paper
• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study

  2011cited by this paper
• Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.

  2011cited by this paper
• RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression

  2010cited by this paper
• Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

  2010cited by this paper
• Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

  2010cited by this paper
• Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells

  2010cited by this paper
• Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.

  2009cited by this paper
• Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti‐hormone therapy and reduced patient survival

  2009cited by this paper
• TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.

  2007cited by this paper
• Wwox and Ap2gamma expression levels predict tamoxifen response.

  2007cited by this paper
• Wwox and Ap2γ Expression Levels Predict Tamoxifen Response

  2007cited by this paper
• Common markers of proliferation

  2006cited by this paper
• Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo

  2006cited by this paper
• Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

  2005cited by this paper
• Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study

  2005cited by this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• GATA‐3 is expressed in association with estrogen receptor in breast cancer

  1999cited by this paper
• PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.

  1997cited by this paper
• Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2

  2026cites this paper
• Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis

  2025cites this paper
• ANOS1 accelerates the progression of esophageal cancer identified by multi-omic approaches.

  2024cites this paper
• Mining and analysis of adverse event signals of vandetanib based on the FAERS database

  2024cites this paper
• Crucial role of the transcription factors family activator protein 2 in cancer: current clue and views

  2023cites this paper
• Ferroptosis Inducers as Promising Radiosensitizer Agents in Cancer Radiotherapy.

  2023cites this paper
• The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy.

  2023cites this paper
• TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB

  2022cites this paper
• Roles of activator protein-2 gamma in breast cancer: A narrative review (SANRA)

  2022cites this paper
• Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.

  2021cites this paper
• WWOX Loses the Ability to Regulate Oncogenic AP-2γ and Synergizes with Tumor Suppressor AP-2α in High-Grade Bladder Cancer

  2021cites this paper
• Deciphering the signaling network of breast cancer improves drug sensitivity prediction.

  2021cites this paper
• Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C

  2021influential citation
• Ferroptosis-related genes are potential prognostic molecular markers for patients with colorectal cancer

  2021cites this paper
• TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition

  2020cites this paper
• A TGF-β– and p63-Responsive Enhancer Regulates IFN-κ Expression in Human Keratinocytes

  2020cites this paper
• Transcription factors in ferroptotic cell death

  2020cites this paper
• MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis.

  2020cites this paper
• Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors

  2020cites this paper
• METTL3 potentiates resistance to cisplatin through m6A modification of TFAP2C in seminoma

  2020cites this paper
• Globally learning gene regulatory networks based on hidden atomic regulators from transcriptomic big data

  2020cites this paper
• The biological characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancers

  2019cites this paper
• Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells

  2019cites this paper
• A Novel Cox Proportional Hazards Model for High-Dimensional Genomic Data in Cancer Prognosis

  2019cites this paper
• Targets and molecular mechanisms of a citrus flavonoid, hesperidin, against luminal breast cancer cells: an integrative bioinformatics analysis

  2019cites this paper
• RET in breast cancer: pathogenic implications and mechanisms of drug resistance

  2019cites this paper
• TFAP2C regulates carbonic anhydrase XII in human breast cancer

  2019cites this paper
• TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells

  2019cites this paper
• An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment

  2019cites this paper
• TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

  2018cites this paper
• Bioinformatics analysis of microarray data to reveal the pathogenesis of diffuse intrinsic pontine glioma

  2018cites this paper
• Potential Anticancer Mechanisms of a Novel EGFR/DNA-Targeting Combi-Molecule (JDF12) against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis

  2017cites this paper
• Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer

  2017cites this paper
• New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies

  2016cites this paper
• Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis

  2016cites this paper